astria therapeutics glp-1 receptor agonist weight management diabetes treatments Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review GLP-1 receptor agonists | How
Description
M., El-Kholy Ael, L., & El-Mesallamy, H
AMP-activated protein kinase inhibits NF-B signaling and inflammation: impact on healthspan and lifespan
Bu H, Li L, Li X, Guo J
10.2337/diabetes.52.1.102 15 ChenH.LiX.ChenJ.RenT.ZhangY.WangY.et al (2023)
Moreover, the SURMOUNTMMO (tirzepatide, NCT05556512) will assess the impact of the dual GLP-1/GIP RA in cardiovascular outcomes and all-cause mortality for people with obesity (without diabetes) when the REDEFINE-3 study will assess the impact of cagrisema in people with obesity (with and without T2DM) and established cardiovascular disease
